Efgartigimod alfa / hyaluronidase Side Effects

Medically reviewed by Drugs.com. Last updated on Nov 22, 2023.

Applies to efgartigimod alfa / hyaluronidase: subcutaneous solution.

Serious side effects

Along with its needed effects, efgartigimod alfa/hyaluronidase may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking efgartigimod alfa / hyaluronidase:

More common

• Bladder pain
• bloody or cloudy urine
• cough
• difficult, burning, or painful urination
• difficulty in moving
• fever
• frequent urge to urinate
• joint pain
• lower back or side pain
• muscle aches, cramps, pain, or stiffness
• sneezing
• sore throat
• swollen joints

Incidence not known

• Difficulty in breathing or swallowing
• fast heartbeat
• large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
• skin itching, rash, or redness
• swelling of the face, throat, or tongue
• trouble breathing

Other side effects

Some side effects of efgartigimod alfa / hyaluronidase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
• headache

For Healthcare Professionals

Applies to efgartigimod alfa / hyaluronidase: subcutaneous solution.

General

The adverse reactions observed in at least 10% of patients treated with efgartigimod alfa-fcab, included respiratory tract infection, headache, and urinary tract infection. The most common adverse reactions reported in at least 10% of patients treated with this combination product, were injection site reactions and headache.^[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (10%)^[Ref]

Local

Very common (10% or more): Injection site reactions (injection site rash, erythema, pruritus, bruising, pain, and urticaria; 38%)^[Ref]

All observed injection site reactions were of mild to moderate severity and did not result in the discontinuation of treatment.^[Ref]

Musculoskeletal

Common (1% to 10%): Myalgia^[Ref]

Nervous system

Very common (10% or more): Headache (include migraine and procedural headache; 32%)

Common (1% to 10%): Paraesthesia (include oral hypoesthesia, hypoesthesia, and hyperesthesia)^[Ref]

Respiratory

Very common (10% or more): Respiratory tract infection (33%)^[Ref]

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer